Cite
APA Citation
Zhou, C., Chen, G., Huang, Y., Chen, J., Cheng, Y., Wang, Q., Pan, Y., Zhou, J., Shi, J., Xu, X., Lin, L., Zhang, W., Zhang, Y., Liu, Y., Fang, Y., Feng, J., Wang, Z., Tai, Y., Ma, X., & Lu, X. (n.d.). 135P Camrelizumab plus chemotherapy as first-line therapy for NSCLC: A pooled analysis of two randomized phase III trials with extended follow-up. Immuno-oncology technology, 16, . http://access.bl.uk/ark:/81055/vdc_100172070425.0x000007